Recent Patent Reform Bills and Their Implications for Prescription Drugs
JAMA · 14.02.2023 · 329 (6) · 459
DOI: 10.1001/jama.2022.24983 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 14.02.2023. Verfasst von S Sean Tu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Wo…. Hauptthemen laut MEDLINE: Health Care Reform, Prescription Drugs, Legislation, Drug, Patents as Topic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint discusses 3 bills introduced recently in Congress that focus on patent eligibility, fraud, and quality and that have major implications for clinical medicine and pharmaceutical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
- West Virginia University College of Law, Morgantown.
- Harvard University, Cambridge, Massachusetts.
- Harvard Medical School, Boston, Massachusetts.
Zitieren
APA
Tu, S. S., Nagar, S., & Kesselheim, A. S. (2023). Recent Patent Reform Bills and Their Implications for Prescription Drugs. JAMA, 329(6), 459. https://doi.org/10.1001/jama.2022.24983
Vancouver
Tu SS, Nagar S, Kesselheim AS. Recent Patent Reform Bills and Their Implications for Prescription Drugs. JAMA. 2023;329(6):459. doi:10.1001/jama.2022.24983
BibTeX
@article{Tu2023,
author = {Tu, S Sean and Nagar, Sarosh and Kesselheim, Aaron S},
title = {Recent Patent Reform Bills and Their Implications for Prescription Drugs},
journal = {JAMA},
year = {2023},
volume = {329},
number = {6},
pages = {459},
doi = {10.1001/jama.2022.24983}
}
EUVIMED